Search

Your search keyword '"R. Hörmann"' showing total 129 results
Start Over Author "R. Hörmann"
129 results on '"R. Hörmann"'

3. Assessment of Tribo-charging and Continuous Feeding Performance of Direct Compression Grades of Isomalt and Mannitol Powders

Author

Michela Beretta, Julia Kruisz, Theresa R. Hörmann-Kincses, Viktoria Magosi, Meishan Guo, Majid Naderi, Sarah Heupl, Johann Kastner, Martin Spoerk, and Amrit Paudel

Subjects
Ecology, Drug Discovery, Pharmaceutical Science, General Medicine, Aquatic Science, Agronomy and Crop Science, Ecology, Evolution, Behavior and Systematics
Abstract

Tribo-charging is often a root cause of mass flow deviations and powder adhesion during continuous feeding. Thus, it may critically impact product quality. In this study, we characterized the volumetric (split- and pre-blend) feeding behavior and process-induced charge of two direct compression grades of polyols, galenIQ™ 721 (G721) for isomalt and PEARLITOL® 200SD (P200SD) for mannitol, under different processing conditions. The feeding mass flow range and variability, hopper end fill level, and powder adhesion were profiled. The feeding-induced tribo-charging was measured using a Faraday cup. Both materials were comprehensively characterized for relevant powder properties, and their tribo-charging was investigated for its dependence on particle size and relative humidity. During split-feeding experiments, G721 showed a comparable feeding performance to P200SD with lower tribo-charging and adhesion to the screw outlet of the feeder. Depending on the processing condition, the charge density of G721 ranged from -0.01 up to -0.39 nC/g, and for P200SD from -3.19 up to -5.99 nC/g. Rather than differences in the particle size distribution of the two materials, their distinct surface and structural characteristics were found as the main factors affecting their tribo-charging. The good feeding performance of both polyol grades was also maintained during pre-blend feeding, where reduced tribo-charging and adhesion propensity was observed for P200SD (decreasing from -5.27 to -0.17 nC/g under the same feeding settings). Here, it is proposed that the mitigation of tribo-charging occurs due to a particle size-driven mechanism. Graphical abstract

Published
2023
Full Text
View/download PDF

4. Predicting powder feedability: A workflow for assessing the risk of flow stagnation and defining the operating space for different powder-feeder combinations

Author

Theresa R. Hörmann-Kincses, Michela Beretta, Julia Kruisz, Fanny Stauffer, Gudrun Birk, Patrick M. Piccione, James Holman, and Johannes G. Khinast

Subjects
Emollients, Chemistry, Pharmaceutical, Pharmaceutical Science, Technology, Pharmaceutical, Powders, Workflow
Abstract

Powder feeding is of critical importance for continuous manufacturing (CM) since next to in-process segregation it is the phenomenon primarily responsible for fluctuations in content uniformity and for content deviations in the final drug product. So far, feeding studies have focused on the characterization of specific feeders and the prediction of their performance for various materials. This work presents a more holistic approach, an early general assessment of the "feedability" of raw materials. With that regard, we established a workflow to: i) predict potential feeding issues, such as the flow stagnation in the hopper based on both the material attributes and the feeder's geometry; and ii) predict the feed rate space using various feeder/screw combinations for powders with an acceptable risk of hopper flow stagnation. Statistical models were developed for this twofold approach using a dataset comprising nine powders and four different feeders. In order to include different feeding equipment into the statistical models, novel equipment descriptors (capturing the effect of different geometries) and performance indicators (the end fill level as indicator for the risk of powder flow stagnation) were introduced. The application of the workflow was demonstrated for a simple formulation, and model validation was successfully performed for an additional powder that was not contained in the original dataset. Finally, the most relevant material attributes were identified, and reduced material characterization data sets were investigated in terms of effects on the model's prediction performance. The workflow presents a promising tool for initial process assessment in early-phase development.

Published
2022

7. Funktionelle Anatomie der Lenden-Becken-Hüft-Region

Author

K.-H. Künzel and R. Hörmann

Subjects
Complementary and Manual Therapy, Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, Complementary and alternative medicine, business.industry, medicine, Physical Therapy, Sports Therapy and Rehabilitation, business, 030205 complementary & alternative medicine
Abstract

Im Rahmen der vielseitigen manualtherapeutischen Konzepte zur Behandlung schmerzhafter Lasionen und Dysfunktionen ist die Anatomie der Lenden-Becken-Huft-Region in ihrer Komplexizitat von groser Bedeutung. Als Themenschwerpunkte wird auf die Funktionalitat der Lendenwirbelsaule und des lumbosakralen Ubergangs sowie auf das Becken als Ganzes unter besonderer Berucksichtigung der Symphysis pubica und der Iliosakralgelenke eingegangen. In Bezug auf die statische Stabilitat und dynamische Balance des Rumpfs als auch im Hinblick auf die Mobilitat in den verschiedenen Bewegungsmustern wird das funktionelle Zusammenspiel der Rumpf-Huft-Muskulatur und die Bedeutung faszialer Strukturen wie der Fascia thoracolumbalis naher erlautert. Hinsichtlich schmerzhafter Lasionen unterschiedlichster Kausalitat wird des Weiteren auf die enge topographische Beziehung der nervalen Strukturen zum muskuloskeletalen System eingegangen.

Published
2018
Full Text
View/download PDF

8. Organkomplikationen der Hyperthyreose

Author

P.M. Schumm-Draeger and R. Hörmann

Subjects
Nephrology, endocrine system, medicine.medical_specialty, endocrine system diseases, business.industry, Thyroid disease, Thyroid, Disease, Hepatology, Bioinformatics, medicine.disease, medicine.anatomical_structure, Internal medicine, Epidemiology, Internal Medicine, medicine, business, Hormone, Subclinical infection
Abstract

Patients with hyperthyroidism tend to feel well and procrastinate the visit to the doctor and hence diagnosis of the disease. Among a whole variety of more or less distinct symptoms affecting many organs, cardiovascular disease is most prevalent and serious, because it relates to an increase in mortality of patients with hyperthyroidism. Recent epidemiological studies have clearly demonstrated that the disease already begins with the subclinical states of hyperthyroidism and, as a consequence, treatment should also be commenced early on. Novel insights into the mechanisms and actions of thyroid hormones at the pathophysiological level offer a potential for the development and future therapeutic use of selective hormone analogues. Despite the high frequency and importance of thyroid disorders, awareness appears to be decreasing and over-dosage of thyroid hormones in benign thyroid conditions is frequent. This review should emphasize that the thyroid gland affects the structure and function of a multitude of organs and, on the other hand, many symptoms and complaints, related to various organ systems, should raise suspicion of thyroid disease.

Published
2010
Full Text
View/download PDF

9. CMS Collaboration

Author

Aarrestad, T.K. Abbaneo, D. Abbiendi, G. Abbrescia, M. Abdelalim, A.A. Abdullin, S. Abdulsalam, A. Abu Zeid, S. Ackert, A. Acosta, D. Acosta, J.G. Adair, A. Adam, W. Adams, J.R. Adams, M.R. Adams, T. Adiguzel, A. Adzic, P. Afanasiev, S. Agapitos, A. Aggleton, R. Agram, J.-L. Ahmad, A. Ahmad, M. Ahmad, M. Ahmed, I. Ahuja, S. Akbiyik, M. Akchurin, N. Akgun, B. Akin, I.V. Albajar, C. Albrow, M. Alcaraz Maestre, J. Aldá Júnior, W.L. Aldaya Martin, M. Alderweireldt, S. Aleksandrov, A. Alexander, J. Alimena, J. Alunni Solestizi, L. Alverson, G. Alves, F.L. Alves, G.A. Alyari, M. Amapane, N. Amsler, C. Anagnostou, G. Anderson, D. Anderson, I. Andrea, J. Andreev, V. Andreev, Y. Andrews, M.B. Androsov, K. Anelli, C. Antonelli, L. Antropov, I. Antunovic, Z. Apanasevich, L. Apollinari, G. Appelt, E. Apresyan, A. Apyan, A. Arcaro, D. Arcidiacono, R. Arenton, M.W. Argiro, S. Arneodo, M. Arora, S. Asavapibhop, B. Asawatangtrakuldee, C. Asilar, E. Asin, I. Askew, A. Ata, M. Attikis, A. Aubin, A. Auffray, E. Autermann, C. Auzinger, G. Avdeeva, E. Avery, P. Avetisyan, A. Avila, C. Awad, A. Azarkin, M. Azhgirey, I. Aziz, T. Azzi, P. Azzolini, V. Azzurri, P. Baarmand, M.M. Baber, M. Bacchetta, N. Bachmair, F. Bachtis, M. Baden, A. Baffioni, S. Bagliesi, G. Baillon, P. Bainbridge, R. Bakhshiansohi, H. Ball, A.H. Ball, F. Ban, Y. Banerjee, S. Banerjee, S. Bäni, L. Bansal, S. Barbagli, G. Barberis, E. Barbieri, R. Bargassa, P. Baringer, P. Barker, A. Barnes, V.E. Barnett, B.A. Barney, D. Baron, O. Barone, L. Barria, P. Bartek, R. Barth, C. Bartók, M. Bartosik, N. Basegmez, S. Baskakov, A. Battilana, C. Baty, A. Bauerdick, L.A.T. Baumgartel, D. Baus, C. Bayshev, I. Bean, A. Beauceron, S. Beaudette, F. Beck, L. Beernaert, K. Behnamian, H. Behnke, O. Behrens, U. Bein, S. Beirão Da Cruz E Silva, C. Belchior Batista Das Chagas, E. Belforte, S. Beliy, N. Belknap, D.A. Bell, A.J. Bellan, R. Belloni, A. Beluffi, C. Belyaev, A. Belyaev, A. Benaglia, A. Benato, L. Bencze, G. Bendavid, J. Benedetti, D. Benelli, G. Benhabib, L. Beni, N. Benitez, J.F. Benucci, L. Benussi, L. Benvenuti, A.C. Beranek, S. Beretvas, A. Bergauer, T. Berger, J. Beri, S.B. Bernardes, C.A. Bernardini, J. Bernet, C. Berruti, G.M. Berry, D. Berry, E. Berryhill, J. Bertl, W. Besancon, M. Betchart, B. Betts, R.R. Bhardwaj, A. Bhat, P.C. Bhatnagar, V. Bhattacharya, S. Bhattacharya, S. Bhopatkar, V. Bhowmik, S. Bialkowska, H. Bian, J.G. Bianchini, L. Bianco, S. Biasini, M. Bierwagen, K. Biino, C. Bilei, G.M. Bilin, B. Bilki, B. Bilmis, S. Bitioukov, S. Blekman, F. Blobel, V. Bloch, D. Bloch, P. Bloom, K. Bluj, M. Blumenfeld, B. Boccali, T. Bocci, A. Bochenek, J. Bodek, A. Bodlak, M. Boimska, B. Boletti, A. Bolla, G. Bonacorsi, D. Bonato, A. Bondu, O. Boos, E. Bornheim, A. Borras, K. Bortignon, P. Bortoletto, D. Borzou, A. Bose, S. Bose, T. Böser, C. Botta, C. Boudoul, G. Bouhali, O. Bourilkov, D. Bouvier, E. Bradmiller-Feld, J. Braghieri, A. Braibant-Giacomelli, S. Branca, A. Brandstetter, J. Brandt, S. Branson, J.G. Breedon, R. Breto, G. Breuker, H. Brew, C. Brianza, L. Brigliadori, L. Brigljevic, V. Brinkerhoff, A. Brinson, J. Brito, L. Brochero Cifuentes, J.A. Brochet, S. Brodski, M. Brom, J.-M. Brona, G. Brondolin, E. Brooke, J.J. Brown, R.M. Brun, H. Bruner, C. Bruno, G. Buchmuller, O. Bucinskaite, I. Bundock, A. Bunin, P. Bunkowski, K. Bunn, J. Buontempo, S. Burgmeier, A. Burkett, K. Burt, K. Burton, D. Busson, P. Busza, W. Butler, J.N. Butler, P.H. Buttignol, M. Butz, E. Bylinkin, A. Bylsma, B. Byszuk, A. Cabrera, A. Cabrillo, I.J. Cadamuro, L. Caillol, C. Cakir, A. Calabria, C. Calamba, A. Calderon, A. Calderon De La Barca Sanchez, M. Cali, I.A. Call, K. Calligaris, L. Calpas, B. Calvelli, V. Calvert, B. Calvo, E. Caminada, L. Campagnari, C. Campanini, R. Campbell, A. Camporesi, T. Candelise, V. Canelli, M.F. Cankocak, K. Capiluppi, P. Cappello, G. Caputo, C. Cardaci, M. Carlsmith, D. Carlson, B. Carnes, A. Carrillo Montoya, C.A. Carrillo Moreno, S. Cartiglia, N. Carvalho, W. Carver, M. Casal, B. Casarsa, M. Casasso, S. Casimiro Linares, E. Castaldi, R. Castaneda Hernandez, A. Castello, R. Castiñeiras De Saa, J.R. Castilla-Valdez, H. Castro, A. Caudron, A. Cavallari, F. Cavallo, F.R. Cavallo, N. Cavanaugh, R. Ceard, L. Celik, A. Centis Vignali, M. Cepeda, M. Cerati, G.B. Cerci, S. Cerminara, G. Cerrada, M. Chabert, E.C. Chamizo Llatas, M. Chang, P. Chang, Y.H. Chang, Y.W. Chanon, N. Chao, Y. Chaparro Sierra, L.F. Chapon, E. Charaf, O. Charlot, C. Chasco, M. Chatterjee, A. Chatterjee, K. Chatterjee, R.M. Chauhan, S. Chauhan, S. Chaves, J. Chawla, R. Chen, G.M. Chen, H.S. Chen, K.F. Chen, K.H. Chen, M. Chen, P.H. Chen, Y. Chen, Z. Cheng, T. Cherepanov, V. Chertok, M. Cheung, H.W.K. Chhibra, S.S. Chierici, R. Chinellato, J. Chiochia, V. Chiorboli, M. Chlebana, F. Choi, M. Choi, S. Choi, Y. Chou, J.P. Choudhary, B.C. Choudhury, S. Chu, J. Chudasama, R. Chwalek, T. Ciangottini, D. Cieri, D. Cihangir, S. Cimmino, A. Ciocci, M.A. Cirkovic, P. Citron, M. Cittolin, S. Ciulli, V. Civinini, C. Claes, D.R. Clare, R. Clarida, W. Clarke, C. Clement, E. Clerbaux, B. Cockerill, D.J.A. Codispoti, G. Colafranceschi, S. Colaleo, A. Cole, J.E. Colino, N. Collard, C. Colling, D. Colombo, F. Contardo, D. Conte, E. Contreras-Campana, C. Contreras-Campana, E. Conway, J. Conway, R. Cooper, S.I. Cornelis, T. Corpe, L. Correa Martins Junior, M. Cossutti, F. Costa, M. Costa, S. Costanza, F. Coubez, X. Couderc, F. Coughlan, J.A. Courbon, B. Cousins, R. Covarelli, R. Cowden, C. Cox, B. Cox, P.T. Creanza, D. Cripps, N. Cristella, L. Crucy, S. Cuevas, J. Cuffiani, M. Cumalat, J.P. Curry, D. Cussans, D. Custódio, A. Cutts, D. Czellar, S. D'Agnolo, R.T. D'Alessandro, R. D'Alfonso, M. D'Hondt, J. Da Costa, E.M. Da Silveira, G.G. Dabrowski, A. Daci, N. Dahmes, B. Dahms, T. Dalchenko, M. Dall'Osso, M. Dallavalle, G.M. Damgov, J. Daponte, V. Das, S. Daskalakis, G. Dasu, S. Dauncey, P. David, A. Davies, G. Davignon, O. De Roeck, A. De Souza Santos, A. De Wit, A. De Cosa, A. De La Cruz, B. De Oliveira Martins, C. De Jesus Damiao, D. De La Cruz-Burelo, E. De Wolf, E.A. De Guio, F. De Lentdecker, G. De Bruyn, I. De Gruttola, M. De Mattia, M. De Palma, M. De Filippis, N. De Castro Manzano, P. De Visscher, S. De Boer, W. Degano, A. Deiters, K. Dejardin, M. Del Re, D. Delaere, C. Delannoy, A.G. Delgado, A. Delgado Peris, A. Dell'Orso, R. Della Ricca, G. Della Negra, M. Demaria, N. Demina, R. Demiragli, Z. Demiroglu, Z.S. Denegri, D. Depasse, P. Derdzinski, M. Dermenev, A. Deroover, K. Descroix, A. Dev, N. Dewanjee, R.K. Dey, S. Dhingra, N. Di Francesco, A. Di Mattia, A. Di Marco, E. Di Matteo, L. Di Guida, S. Diamond, B. Diemoz, M. Dierlamm, A. Dietz, C. Dietz-Laursonn, E. Diez Pardos, C. Dildick, S. Dilsiz, K. Dimitrov, A. D'imperio, G. Dinardo, M.E. Dishaw, A. Dissertori, G. Dittmann, J. Dittmar, M. Dittmer, S. Doan, T.H. Dobson, M. Dobur, D. Dodd, L. Dogra, S. Dolen, J. Dolinska, G. Dominguez, A. Domínguez Vázquez, D. Donato, S. Donegà, M. Dooling, S. Dordevic, M. Dorigo, T. Dorland, T. Dorney, B. Doroba, K. Dozen, C. Draeger, A.R. Dragicevic, M. Dragoiu, C. Dremin, I. Driga, O. Du, R. Duarte, J. Dube, S. Duchardt, D. Dudenas, V. Dudero, P.R. Dugad, S. Duggan, D. Dumanoglu, I. Dunne, P. Dünser, M. Dupont, N. Durgut, S. Duric, S. Durkin, L.S. Dutta, D. Dutta, S. Dutta, V. Eckerlin, G. Ecklund, K.M. Eckstein, D. Edelhoff, M. Eerola, P. Eggert, N. Eichhorn, T. El Mamouni, H. El Sawy, M. Eller, P. Elliott-Peisert, A. Ellison, J. Elmer, P. Elvira, V.D. Elwood, A. Eminizer, N. Endres, M. Eno, S.C. Epshteyn, V. Erbacher, R. Erdmann, M. Erdmann, W. Erdogan, Y. Erdweg, S. Erfle, J. Erö, J. Ershov, A. Escalante Del Valle, A. Esch, T. Eshaq, Y. Esposito, M. Etesami, S.M. Eusebi, R. Evangelou, I. Evans, A. Evdokimov, O. Everaerts, P. Fabbri, F. Fabbri, F. Fabbro, B. Fabozzi, F. Faccioli, P. Fagot, A. Fahim, A. Fan, J. Fanfani, A. Fangmeier, C. Fanò, L. Fantasia, C. Fanzago, F. Farrell, C. Fasanella, D. Fasanella, G. Faulkner, J. Faure, J.L. Favaro, C. Favart, D. Favart, L. Fay, J. Fedi, G. Fehling, D. Felcini, M. Feld, L. Feng, L. Ferapontov, A. Ferbel, T. Ferencek, D. Ferguson, T. Ferguson, W. Fernandez Bedoya, C. Fernandez Menendez, J. Fernández Ramos, J.P. Fernandez, M. Fernandez Perez Tomei, T.R. Ferraioli, C. Ferreira Parracho, P.G. Ferri, F. Ferro, F. Field, R.D. Filipovic, N. Finco, L. Finger, M., Jr. Finger, M. Fink, S. Finkel, A. Fiore, L. Fiorendi, S. Fiori, F. Fischer, R. Fisk, I. Flacher, H. Flechl, M. Flix, J. Florent, A. Florez, C. Flouris, G. Flowers, K. Flowers, S. Flucke, G. Flügge, G. Foà, L. Focardi, E. Foerster, M. Folgueras, S. Fonseca De Souza, S. Fontaine, J.-C. Ford, W.T. Forthomme, L. Foudas, C. Fouz, M.C. Francis, B. Franco Sevilla, M. Franzoni, G. Freeman, J. Frensch, F. Friedl, M. Friese, R. Frueboes, T. Frühwirth, R. Fulcher, J. Funk, W. Furic, I.K. Futyan, D. Gadrat, S. Galanti, M. Gallinaro, M. Gallo, E. Galloni, C. Gandrajula, R.P. Ganguly, S. Ganjour, S. Garabedian, A. Garay Garcia, J. Garcia, G. Garcia-Abia, P. Garcia-Bellido, A. Garcia-Ferrero, J. Gardner, M. Garg, R.B. Garutti, E. Gary, J.W. Gascon, S. Gastler, D. Gauthier, L. Gavrilenko, M. Gavrilov, V. Gaz, A. Geenen, H. Geffert, P. Geiser, A. Geisler, M. Gelé, D. Gelli, S. Gennai, S. George, C. George, J. Geralis, T. Gerber, C.E. Gerosa, R. Gershtein, Y. Geurts, F.J.M. Ghete, V.M. Ghezzi, A. Ghosh, S. Giacomelli, P. Giakoumopoulou, V.A. Giammanco, A. Giassi, A. Giffels, M. Gigi, D. Gilbert, A. Gill, K. Gilmore, J. Giordano, D. Giordano, F. Girgis, S. Girone, M. Givernaud, A. Gizhko, A. Glege, F. Gleyzer, S.V. Glushkov, I. Gninenko, S. Go, Y. Gobbo, B. Godinovic, N. Godshalk, A. Goebel, K. Goerlach, U. Goetzmann, C. Goh, J. Gokbulut, G. Goldouzian, R. Goldstein, J. Golf, F. Golovtsov, V. Golubev, N. Golutvin, I. Gomber, B. Gomez Moreno, B. Gomez Ceballos, G. Gomez, G. Gomez, J.A. Gomez, J.P. Goncharov, M. Gonella, F. Gonzalez, D. Gonzalez Caballero, I. Gonzalez Lopez, O. Gonzalez Suarez, R. Gonzi, S. Goodell, J. Gorbunov, I. Gori, V. Görner, M. Górski, M. Gottschalk, E. Gouskos, L. Gouzevitch, M. Govoni, P. Goy Lopez, S. Gozzelino, A. Grab, C. Gran, J. Grandi, C. Granier de Cassagnac, R. Gras, P. Gray, L. Gray, R. Grebenyuk, A. Green, D. Greene, S. Gregores, E.M. Gribushin, A. Grimes, M. Grippo, M.T. Gritsan, A.V. Grothe, M. Grundler, U. Grünendahl, S. Grunewald, M. Grynyov, B. Guchait, M. Gude, A. Guida, R. Guiducci, L. Guilbaud, M. Gul, M. Guler, Y. Gulhan, D. Gülmez, E. Gundacker, S. Gunnellini, P. Gupta, R. Gurpinar, E. Gurrola, A. Gurtu, A. Gutay, L. Güth, A. Guthoff, M. Gutsche, O. Gyun, D. Haas, J. Hadjiiska, R. Hadley, N.J. Hagopian, S. Hagopian, V. Hahn, K.A. Haitz, D. Hajdu, C. Hakala, J. Halkiadakis, E. Hall, G. Hall-Wilton, R. Haller, J. Hamel de Monchenault, G. Hamer, M. Hammad, G.H. Hammer, J. Han, J. Hanlon, J. Hansen, P. Hanson, G. Hardenbrook, J. Harder, K. Hare, D. Harel, A. Härkönen, J. Harper, S. Harr, R. Harrington, C. Harris, P. Harris, R.M. Hart, A. Hartl, C. Hartmann, F. Hasegawa, S. Hassan, Q. Hatakeyama, K. Hauk, J. Hauser, J. Haytmyradov, M. Hazi, A. Heath, G.P. Heath, H.F. Hebbeker, T. Hebda, P. Hegeman, J. Heidegger, C. Heidemann, C. Heilman, J. Heindl, S.M. Heintz, U. Heister, A. Hempel, M. Henderson, C. Hensel, C. Heracleous, N. Heredia-De La Cruz, I. Hernandez, J.M. Hernandez-Almada, A. Herndon, M. Hervé, A. Hewamanage, S. Hidas, D. Hidas, P. Hildreth, M. Hill, C. Hindrichs, O. Hinzmann, A. Hirosky, R. Hirschauer, J. Hits, D. Hobson, P.R. Hoehle, F. Hoepfner, K. Hoffmann, M. Hofman, D.J. Hohlmann, M. Höing, R.S. Hollar, J. Holzner, A. Hong, B. Hoorani, H.R. Horisberger, R. Hörmann, N. Hortiangtham, A. Horvath, D. Hos, I. Hoss, J. Hou, W.-S. Hreus, T. Hrubec, J. Hsiung, Y. Hu, Z. Huang, T. Huertas Guativa, L.M. Hughes, E. Hughes, R. Hugon, J. Husemann, U. Iaselli, G. Iashvili, I. Iaydjiev, P. Ibrahim, Z.A. Ignatenko, M. Iiyama, Y. Iles, G. Ille, B. Incandela, J. Ingram, Q. Innocente, V. Innocenti, G.M. Iorio, A.O.M. Isildak, B. Ivanov, A. Ivanov, Y. Ivova PANEVA, M. Jabeen, S. Jacob, J. Jafari, A. Jain, S. Jain, S. Jandir, P. Janjam, R. Janot, P. Janssen, X. Jarry, P. Jayatilaka, B. Jeitler, M. Jensen, F. Jessop, C. Jez, P. Jha, M.K. Jha, V. Ji, W. Jiang, C.H. Jindariani, S. Jo, M. Johns, W. Johnson, A. Johnson, K.F. Johnson, M. Jones, M. Jorda, C. Josa, M.I. Joshi, U. Jung, A.W. Jung, H. Jung, K. Junkes, A. Juodagalvis, A. Kaadze, K. Kachanov, V. Kadastik, M. Kadija, K. Kaestli, H.C. Kaisen, J. Kalafut, S. Kalakhety, H. Kalinin, A. Kalinowski, A. Kalogeropoulos, A. Kalsi, A.K. Kamalieddin, R. Kamenev, A. Kaminskiy, A. Kamon, T. Kangal, E.E. Kanishchev, K. Kao, S.C. Kaplan, S. Karacheban, O. Karancsi, J. Karapinar, G. Karapostoli, G. Karchin, P.E. Kargoll, B. Karimäki, V. Karjavin, V. Karmgard, D.J. Karneyeu, A. Kasemann, M. Kasieczka, G. Katkov, I. Katsas, P. Kaur, A. Kaur, M. Kaya, M. Kaya, O. Kayis Topaksu, A. Kazana, M. Keaveney, J. Kellams, N. Keller, J. Kelley, R. Kellogg, R.G. Kennedy, E. Kenny, R.P., III Kenzie, M. Kesisoglou, S. Khachatryan, V. Khakzad, M. Khalil, S. Khan, A. Khan, W.A. Kharchilava, A. Khatiwada, A. Khristenko, V. Khukhunaishvili, A. Khurana, R. Khurshid, T. Kiani, B. Kiesel, M.K. Kieseler, J. Kilminster, B. Kim, D. Kim, D.H. Kim, G.N. Kim, H. Kim, H. Kim, H. Kim, J.H. Kim, M.S. Kim, T.J. Kim, V. Kim, Y. Kinnunen, R. Kirakosyan, M. Kirsanov, M. Kirschenmann, H. Klabbers, P. Klanner, R. Klapoetke, K. Klein, D. Klein, K. Kleinwort, C. Klima, B. Klute, M. Knowlton, D. Knünz, V. Knutsson, A. Knutzen, S. Ko, W. Koay, S.A. Kodolova, O. Kogler, R. Kokkas, P. Kolberg, T. Kole, G. Komaragiri, J.R. Komm, M. Konecki, M. Kong, D.J. König, A. Konigsberg, J. Konoplyanikov, V. Konstantinov, D. Konyushikhin, M. Kornmayer, A. Korol, I. Korotkikh, V. Kortelainen, M.J. Korytov, A. Kothekar, K. Kotlinski, D. Kotov, K. Kottachchi Kankanamge Don, C. Kousouris, K. Kovac, M. Kovalchuk, N. Kovalskyi, D. Kovitanggoon, K. Krajczar, K. Krammer, M. Krasnikov, N. Krätschmer, I. Kravchenko, I. Kreczko, L. Kreis, B. Kress, T. Kreuzer, P. Krofcheck, D. Krohn, M. Krolikowski, J. Kropivnitskaya, A. Krutelyov, V. Krychkine, V. Kubik, A. Kubota, Y. Kuessel, Y. Kumar, A. Kumar, A. Kumar, A. Kumar, A. Kumar, R. Kumar, S. Kumar, V. Kunkle, J. Kunnawalkam Elayavalli, R. Kunori, S. Künsken, A. Kuo, C.M. Kurt, P. Kuznetsova, E. Kwan, S. Kwon, E. Kyberd, P. Kyriakis, A. La Licata, C. Lacroix, F. Lagarde, F. Lai, Y.S. Laird, E. Laktineh, I.B. Lamichhane, K. Lamichhane, P. Lammel, S. Lampén, T. Lanaro, A. Lander, R. Landsberg, G. Lane, R. Lanev, A. Lange, C. Lange, D. Lange, W. Langenegger, U. Lannon, K. Lanza, G. Lapsien, T. Lariccia, P. Lassila-Perini, K. Lath, A. Lauwers, J. Lawson, P. Le Bihan, A.-C. Lecoq, P. Ledovskoy, A. Lee, B. Lee, J. Lee, J.S.H. Lee, K. Lee, K.S. Lee, S. Lee, S. Lee, S.W. Lee, Y.-J. Leggat, D. Lehti, S. Lelas, D. Lemaitre, V. Lenz, T. Lenzi, P. Lenzi, T. Léonard, A. Leonard, J. Leonardo, N. Leonidov, A. Lesko, Z. Leslie, D. Lethuillier, M. Letts, J. Levchenko, P. Levchuk, L. Levin, A. Levine, A. Li, H. Li, Q. Li, W. Libeiro, T. Ligabue, F. Liko, D. Lin, C. Lin, W. Linacre, J. Lincoln, D. Lindén, T. Ling, T.Y. Lingemann, J. Linn, S. Lipinski, M. Lipka, K. Lipton, R. Lisniak, S. Lista, L. Litov, L. Liu, B. Liu, H. Liu, S. Liu, T. Liu, Y.F. Lloret Iglesias, L. Lo Vetere, M. Lobanov, A. Lobelle Pardo, P. Locci, E. Lohmann, W. Lokhtin, I. Lomtadze, T. Long, K. Long, O.R. Longo, E. Lopes De Sá, R. Lopez Virto, A. Lopez-Fernandez, R. Loukas, D. Loukas, N. Lourenço, C. Loveless, R. Low, J.F. Lowette, S. Lu, R.-S. Lu, Y. Lu, Y.J. Lucas, C. Lucas, R. Lucchini, M.T. Luckey, P.D. Luetic, J. Lujan, P. Luo, W. Lustermann, W. Luthra, A. Luukka, P. Luyckx, S. Lychkovskaya, N. Lykken, J. Lyons, L. Ma, P. Machet, M. Macneill, I. Mäenpää, T. Maerschalk, T. Maeshima, K. Maggi, G. Maggi, M. Magini, N. Magnan, A.-M. Magnani, A. Maguire, C. Mahakud, B. Mahrous, A. Maier, B. Maity, M. Majumdar, N. Majumder, D. Majumder, G. Makouski, M. Makovec, A. Maksimovic, P. Mal, P. Malakhov, A. Malberti, M. Malbouisson, H. Malcles, J. Malek, M. Malgeri, L. Malhotra, S. Malik, S. Malik, S. Malvezzi, S. Mandal, K. Mangano, B. Mankel, R. Mannelli, M. Mans, J. Manthos, N. Mantovani, G. Manzoni, R.A. Mao, Y. Mao, Y. Mao, Z. Maravin, Y. Marcellini, S. Marchesini, I. Marco, J. Marco, R. Marconi, D. Marfin, I. Margaroli, F. Margoni, M. Marinelli, N. Marini, A.C. Marinov, A. Marionneau, M. Mariotti, C. Markowitz, P. Marlow, D. Maron, G. Marone, M. Marraffino, J.M. Martelli, A. Martin, C. Martinez Rivero, C. Martinez, G. Martinez Ruiz del Arbol, P. Martinez Outschoorn, V.I. Martini, L. Maruyama, S. Marzocchi, B. Masciovecchio, M. Maselli, S. Masetti, G. Masetti, L. Mason, D. Massironi, A. Mastrolorenzo, L. Matchev, K. Matorras, F. Matos Figueiredo, D. Matsushita, T. Matveev, V. Mavromanolakis, G. Mazumdar, K. McBride, P. Mccartin, J. Mccoll, N. Mcginn, C. Md Ali, M.A.B. Medvedeva, T. Mehta, A. Mei, H. Meier, F. Meijers, F. Meister, D. Melo, A. Melzer-Pellmann, I.-A. Menasce, D. Meneguzzo, A.T. Meng, F. Meng, Z. Menichelli, M. Meola, S. Mercadante, P.G. Meridiani, P. Merkel, P. Merlin, J.A. Merlo, J.-P. Mermerkaya, H. Merola, M. Merschmeyer, M. Mersi, S. Mertens, A. Meschi, E. Meschini, M. Messineo, A. Mestvirishvili, A. Mesyats, G. Meyer, A. Meyer, A.B. Meyer, M. Miñano Moya, M. Micanovic, S. Micheli, F. Michelotto, M. Michlin, B. Migliore, E. Mignerey, A.C. Mikulec, I. Mildner, H. Milenovic, P. Miller, D.H. Millet, P. Milosevic, J. Miné, P. Miniello, G. Mirabito, L. Mirman, N. Mironov, C. Mishra, K. Misiura, M. Missiroli, M. Mitra, S. Mitselmakher, G. Mittag, G. Mittal, M. Mnich, J. Modak, A. Moeller, A. Mohamad Idris, F. Mohammadi, A. Mohammadi Najafabadi, M. Mohanty, A.K. Mohanty, G.B. Mohapatra, A. Moisenz, P. Molnar, J. Monaco, V. Mondal, K. Monge, M.R. Monroy, J. Montagna, P. Montanari, A. Montecassiano, F. Monteil, E. Moon, C.S. Mooney, M. Moortgat, F. Mora Herrera, C. Moraes, A. Moran, D. Moreels, L. Morelos Pineda, A. Moroni, L. Morovic, S. Morse, D.M. Mossolov, V. Mott, A. Mousa, J. Mozer, M.U. Mrenna, S. Mucia, N. Mueller, C. Mueller, R. Mukherjee, S. Mukhopadhyay, S. Mulders, M. Mulhearn, M. Mulholland, T. Müller, T. Müller, T. Mullin, S.D. Mundim, L. Murray, M. Murumaa, M. Murzin, V. Musella, P. Musich, M. Musienko, Y. Mussgiller, A. My, S. Myagkov, I. Nachtman, J. Nahn, S. Naimuddin, M. Nam, S.K. Narain, M. Naranjo, I.N. Narayanan, S. Naseri, M. Nash, D. Nash, J. Nash, K. Nauenberg, U. Naumann-Emme, S. Navarria, F.L. Navarro De Martino, E. Nawrocki, K. Nayak, A. Nehrkorn, A. Nemallapudi, M.V. Nessi-Tedaldi, F. Neu, C. Neugebauer, H. Neumeister, N. Newbold, D.M. Newman, H.B. Newman-Holmes, C. Ngadiuba, J. Nguyen, F. Nguyen, M. Ni, H. Nicolaou, C. Nicolas Kaufman, G. Nikitenko, A. Nishu, N. Niu, X. Nogima, H. Noonan, D. Northup, M. Nourbakhsh, S. Novaes, S.F. Nowack, A. Nowatschin, D. Ntomari, E. Nugent, I.M. Nuttens, C. Nuzzo, S. O'Brien, C. O'Dell, V. Obertino, M.M. Obraztsov, S. Ocampo Rios, A.A. Ochando, C. Odell, N. Ogul, H. Oh, Y.D. Ojalvo, I. Olaiya, E. Olbrechts, A. Oliveros, S. Olivito, D. Olmedo Negrete, M. Olschewski, M. Olsen, J. Olszewski, M. Onel, Y. Onengut, G. Oreshkin, V. Orfanelli, S. Organtini, G. Orimoto, T. Orsini, L. Ortona, G. Osherson, M. Osipenkov, I. Ostapchuk, A. Ott, J. Ozdemir, K. Ozok, F. Ozturk, S. Pacher, L. Padeken, K. Padhi, S. Padley, B.P. Paganini, P. Paganoni, M. Pakhotin, Y. Paktinat Mehdiabadi, S. Palencia Cortezon, E. Palichik, V. Palla, F. Palmer, C. Panagiotou, A. Pandolfi, F. Pant, L.M. Pantaleo, F. Panwalkar, S. Paoletti, S. Paolucci, P. Papacz, P. Papadopoulos, I. Pape, L. Paradas, E. Paramatti, R. Paramesvaran, S. Parashar, N. Parida, B. Park, I.C. Park, M. Park, S.K. Pashenkov, A. Passaseo, M. Pastika, N. Pastrone, N. Pata, J. Patel, R. Patterson, J.R. Paulini, M. Paus, C. Pauss, F. Pavlov, B. Pazzini, J. Pedraza, I. Pedrini, D. Pedro, K. Pegoraro, M. Peiffer, T. Pekkanen, J. Pela, J. Pellett, D. Pelliccioni, M. Peltola, T. Pena, C. Penzo, A. Pequegnot, A.L. Perelygin, V. Perez, E. Pérez-Calero Yzquierdo, A. Perieanu, A. Perloff, A. Perniè, L. Perrey, H. Perries, S. Perrini, L. Perrotta, A. Perrozzi, L. Perry, T. Peruzzi, M. Pesaresi, M. Petkov, P. Petrakou, E. Petridis, K. Petrilli, A. Petrillo, G. Petrov, V. Petrucciani, G. Petrushanko, S. Petyt, D. Pfeiffer, A. Piccolo, D. Piedra Gomez, J. Pieri, M. Pierini, M. Pierro, G.A. Pietsch, N. Pigard, P. Pilot, J. Pin, A. Pinna, D. Pinna Angioni, G.L. Piotrzkowski, K. Piparo, D. Piperov, S. Piroué, P. Pistone, C. Pitzl, D. Placakyte, R. Plagge, M. Planer, M. Plestina, R. Poehlsen, J. Pol, M.E. Polese, G. Poll, A. Pollack, B. Pompili, A. Pook, T. Pooth, O. Popov, A. Popov, V. Potenza, R. Poyraz, D. Pozdnyakov, A. Pozdnyakov, I. Pozzobon, N. Prado Da Silva, W.L. Preiato, F. Preuten, M. Primavera, F. Prokofyev, O. Prosper, H. Psallidas, A. Ptochos, F. Puerta Pelayo, J. Pugliese, G. Puigh, D. Puljak, I. Python, Q. Qian, S.J. Quast, G. Quertenmont, L. Quintario Olmeda, A. Quittnat, M. Yates, B.R. Rabady, D. Rabbertz, K. Racz, A. Radburn-Smith, B.C. Radi, A. Radogna, R. Radziej, M. Ragazzi, S. Rahatlou, S. Rahbaran, B. Raics, P. Raidal, M. Rakness, G. Ralph, D. Rander, J. Randle-conde, A. Ranieri, A. Ranjan, K. Rank, D. Rankin, D. Rappoccio, S. Raspereza, A. Rathjens, D. Ratnikov, F. Ratti, S.P. Raupach, F. Ravera, F. Raymond, D.M. Razis, P.A. Re, V. Rebassoo, F. Rebello Teles, P. Redaelli, N. Redjimi, R. Redondo, I. Regnard, S. Reid, I.D. Reinsvold, A. Reis, T. Reithler, H. Rekovic, V. Renker, D. Rezaei Hosseinabadi, F. Ribeiro Cipriano, P.M. Riccardi, C. Ricci-Tam, F. Richards, A. Richardson, C. Richman, J. Rieger, M. Riley, G. Rinkevicius, A. Rizzi, A. Roberts, J. Robmann, P. Robutti, E. Röcker, S. Rodenburg, M. Rodozov, M. Rodrigo, T. Rodrigues Antunes, J. Rodriguez, J.L. Rodríguez-Marrero, A.Y. Roh, Y. Rohe, T. Rohlf, J. Rohringer, H. Roland, B. Roland, C. Roland, G. Rolandi, G. Romanowska-Rybinska, K. Romeo, F. Romero, A. Romero Abad, D. Romero, L. Ronchese, P. Ronga, F.J. Roozbahani, B. Rorie, J. Roscher, F. Rose, A. Rose, A. Rose, K. Roskes, J. Rosowsky, A. Rossi, A.M. Rossin, R. Rossini, M. Rovelli, C. Rovelli, T. Rovere, M. Roy, A. Roy, D. Roy Chowdhury, S. Roy, T. Ruan, M. Ruchti, R. Ruckstuhl, N. Ruggles, T. Ruiz Vargas, J.C. Ruiz Alvarez, J.D. Ruiz-Jimeno, A. Rumerio, P. Rusack, R. Rusakov, S.V. Ruspa, M. Russ, J. Ryckbosch, D. Ryd, A. Rykaczewski, H. Ryu, G. Ryu, M.S. Ryutin, R. Padula, S.S. Sabes, D. Sacchi, R. Sady, A. Safarzadeh, B. Safonov, A. Safronov, G. Sagir, S. Saha, A. Sahin, M.Ö. Sahoo, D.K. Sahoo, N. Saini, L.K. Saka, H. Sakharov, A. Sakulin, H. Sakuma, T. Salazar Ibarguen, H.A. Salerno, D. Salerno, R. Salfeld-Nebgen, J. Saltzberg, D. Salur, S. Salva, S. Salvini, P. Sanabria, J.C. Sanchez-Hernandez, A. Sander, C. Sanders, S. Sandoval Gonzalez, I.D. Sani, M. Santanastasio, F. Santaolalla, J. Santocchia, A. Santoro, A. Saoulidou, N. Sarangi, T. Sarica, U. Sarkar, S. Sarkar, T. Sauvan, J.B. Savin, A. Savoy-Navarro, A. Savrin, V. Saxena, P. Schael, S. Schäfer, C. Scharf, C. Schettler, H. Scheuch, F. Schieck, J. Schizzi, A. Schleper, P. Schlieckau, E. Schmidt, A. Schmitt, M. Schnetzer, S. Schoerner-Sadenius, T. Schöfbeck, R. Schröder, M. Schulte, J.F. Schwandt, J. Schwick, C. Sciacca, C. Scodellaro, L. Seez, C. Seidel, M. Seif El Nasr-storey, S. Seitz, C. Seixas, J. Selvaggi, G. Selvaggi, M. Sen, S. Senkin, S. Serban, A.T. Seva, T. Sexton-Kennedy, E. Sgandurra, L. Sguazzoni, G. Shaheen, S.M. Shalhout, S. Sharan, M. Sharma, A. Sharma, A. Sharma, R. Sharma, S. Sharma, V. Sharma, V. Shchutska, L. Sheffield, D. Sheldon, P. Shepherd-Themistocleous, C.H. Shi, X. Shin, Y.H. Shipsey, I. Shmatov, S. Shoaib, M. Shrinivas, A. Shukla, P. Shulha, S. Shumeiko, N. Siado, J.E. Sieber, G. Sigamani, M. Sikler, F. Silkworth, C. Silva, P. Silvers, D. Silvestris, L. Simon, M. Simon, S. Simonetto, F. Simonis, H.J. Singh, G. Singh, J.B. Sinthuprasith, T. Sirois, Y. Siroli, G.P. Sirunyan, A.M. Skatchkov, N. Skhirtladze, N. Skinnari, L. Skovpen, K. Skuja, A. Smirnov, I. Smirnov, V. Smith, D. Smith, G. Smith, J. Smith, N. Smith, V.J. Smith, W.H. Snigirev, A. Snook, B. Snow, G.R. Snowball, M. Snyder, C. Soares, M.S. Sobol, A. Soffi, L. Soha, A. Sola, V. Solano, A. Somalwar, S. Son, D.C. Song, S. Sonnenschein, L. Sordini, V. Sorokin, P. Spagnolo, P. Spalding, W.J. Spanier, S. Spannagel, S. Sperka, D. Sphicas, P. Spiegel, L. Spiezia, A. Spiridonov, A. Spiropulu, M. Squires, M. Srimanobhas, N. St. John, J. Stadie, H. Stahl, A. Staiano, A. Starodumov, A. Steggemann, J. Steinbrück, G. Stenson, K. Stephans, G.S.F. Stickland, D. Stieger, B. Stober, F.M. Stolp, D. Stone, R. Stoye, M. Stoykova, S. Stoynev, S. Strauss, J. Strebler, T. Stringer, R. Strobbe, N. Strologas, J. Strom, D. Stuart, D. Stupak, J. Sturdy, J. Suarez, I. Suarez Gonzalez, J. Sudic, L. Sulak, L. Sulimov, V. Sultanov, G. Sumorok, K. Sun, J. Sun, M. Sun, W. Sun, X. Sung, K. Sur, N. Sutar, B. Suwonjandee, N. Svyatkovskiy, A. Swain, S.K. Swartz, M. Syarif, R. Symonds, P. Szillasi, Z. Szleper, M. Sznajder, A. Tabarelli de Fatis, T. Tadel, M. Takahashi, M. Takahashi, Y. Takasugi, E. Tali, B. Talvitie, J. Tambe, N. Tan, P. Tan, S.M. Tao, J. Tapper, A. Taroni, S. Tatarinov, A. Tavernier, S. Tavolaro, V.R. Taylor, D. Taylor, L. Teixeira De Lima, R. Tenchini, R. Teo, W.D. Teodorescu, L. Terentyev, N. Teyssier, D. Thea, A. Theofilatos, K. Tholen, H. Thom, J. Thomas, L. Thomas, S. Thomassen, P. Thompson, J. Thüer, S. Thyssen, F. Tiko, A. Tiras, E. Titov, M. Tkaczyk, S. Tlisov, D. Toda, S. Toldaiev, O. Tomalin, I.R. Tonelli Manganote, E.J. Tonelli, G. Tonjes, M.B. Tonwar, S.C. Topakli, H. Topkar, A. Topsis-Giotis, I. Torassa, E. Toriashvili, T. Toropin, A. Tosi, M. Tosi, N. Tosi, S. Tourtchanovitch, L. Traczyk, P. Tran, N.V. Trauger, H. Travaglini, R. Treberer-Treberspurg, W. Treille, D. Trevisani, N. Tricomi, A. Triossi, A. Tripathi, M. Trippkewitz, K.D. Trocino, D. Trocsanyi, Z.L. Troendle, D. Tropiano, A. Troshin, S. Trovato, M. Tsai, J.F. Tsamalaidze, Z. Tsirou, A. Tu, Z. Tucker, J. Tully, C. Tumasyan, A. Tuo, S. Tuominen, E. Tuominiemi, J. Tuovinen, E. Turkewitz, J. Turner, M. Turner, P. Tuuva, T. Tuve, C. Tytgat, M. Tyurin, N. Tzeng, Y.M. Tziaferi, E. Bhawandeep, U. Uchida, K. Ujvari, B. Ulmer, K.A. Ulrich, R. Undleeb, S. Uplegger, L. Usai, E. Uvarov, L. Uzunian, A. Vaandering, E.W. Vadruccio, D. Vai, I. Vaitkus, J. Valls, N. Valuev, V. Van Spilbeeck, A. Van Onsem, G.P. Van Haevermaet, H. Van Parijs, I. Van De Klundert, M. Van Remortel, N. Van Mulders, P. Van Mechelen, P. Van Hove, P. Van Doninck, W. Van Driessche, W. Vander Velde, C. Vander Donckt, M. Vanelderen, L. Vanhoefer, A. Vanini, S. Vanlaer, P. Vardanyan, I. Vardarlı, F.I. Varela, J. Varelas, N. Varma, M. Vartak, A. Vavilov, S. Vazquez Valencia, F. Vazquez Acosta, M. Veelken, C. Velasco, M. Velicanu, D. Velkovska, J. Venditti, R. Ventura, S. Venturi, A. Verdier, P. Verdini, P.G. Veres, G.I. Vergili, M. Verlage, T. Vernieri, C. Verwilligen, P. Verzetti, M. Verzocchi, M. Veszpremi, V. Vesztergombi, G. Veverka, J. Vidal Marono, M. Vidal, R. Vila, I. Vilar Cortabitarte, R. Vilela Pereira, A. Viliani, L. Virdee, T. Viret, S. Vischia, P. Vitulo, P. Vizan Garcia, J.M. Vlasov, E. Vlimant, J.R. Vogel, H. Volkov, A. Volobouev, I. Vormwald, B. Vorobiev, I. Vorobyev, A. Voutilainen, M. Vutova, M. Wagner, S.R. Wagner-Kuhr, J. Walczak, M. Walia, G. Walker, M. Wallny, R. Walsh, R. Waltenberger, W. Wan Abdullah, W.A.T. Wang, C. Wang, D. Wang, F. Wang, J. Wang, J. Wang, Q. Wang, R.-J. Wang, S. Wang, T.W. Wang, Y. Wang, Z. Wardle, N. Wasserbaech, S. Wayand, S. Wayne, M. Weber, H. Weber, H.A. Weber, M. Weber, M. Wei, H. Weiler, T. Weinberg, M. Welke, C. Wendland, L. Weng, Y. West, C. Wetzel, J. Whitbeck, A. Wickramage, N. Wilbur, S. Williams, T. Wimpenny, S. Winer, B.L. Wissing, C. Wittich, P. Wittmer, B. Wöhri, H.K. Wöhrmann, C. Wolf, M. Wolf, R. Wolfe, E. Wood, D. Wood, J. Woodard, A. Woods, N. Worm, S.D. Wright, D. Wu, Z. Wulsin, H.W. Wulz, C.-E. Würthwein, F. Wyslouch, B. Xia, F. Xiao, M. Xie, S. Xie, W. Xin, Y. Xu, L. Xu, Q. Xu, Z. Yagil, A. Yalvac, M. Yang, F. Yang, M. Yang, Y. Yazgan, E. Yelton, J. Yetkin, E.A. Yetkin, T. Yi, K. Yilmaz, Y. Yohay, R. Yonamine, R. Yoo, H.D. Yoo, J. York, A. You, C. Yu, I. Yu, S.S. Yumiceva, F. Yusli, M.N. Zabel, J. Zabi, A. Zaganidis, N. Zagozdzinska, A. Zakaria, M. Zalewski, P. Zanetti, A. Zanetti, M. Zarubin, A. Zeinali, M. Zenoni, F. Zenz, S.C. Zeuner, W.D. Zevi Della Porta, G. Zeyrek, M. Zghiche, A. Zhang, F. Zhang, H. Zhang, J. Zhokin, A. Zhu, R.Y. Zhukov, V. Zhukova, V. Zorbilmez, C. Zotto, P. Zou, D. Zsigmond, A.J. Zucchetta, A. Zuranski, A. d'Enterria, D. de Trocóniz, J.F. de Barbaro, P. du Pree, T. CMS Collaboration

Published
2016

10. Medikamentöse Behandlung der Immunhyperthyreose (Typ Morbus Basedow)

Author

R. Hörmann, Onno E. Janssen, B. Quadbeck, and Klaus Mann

Subjects
Secondary prevention, Gynecology, medicine.medical_specialty, business.industry, Internal Medicine, Medicine, business, Morbus Basedow
Abstract

Die Immunhyperthyreose (M. Basedow) ist bis heute keiner kausalen Therapie zuganglich, die symptomatische Behandlung mit Berucksichtigung des naturlichen Verlaufs der Erkrankung steht daher weiter im Vordergrund. Wahrend durch die medikamentose Therapie innerhalb von 4–6 Wochen bei uber 90% der Patienten eine Euthyreose erreicht wird, sind die Langzeitergebnisse mit Rezidivraten von 30–50% unbefriedigend. Gegenstand prospektiver, randomisierter Studien war in den letzten Jahren die Evaluation von Prognoseparametern und der Wirksamkeit von Levothyroxin in der Verhutung des Hyperthyreoserezidivs. Jungste Studien galten der Phase nach antithyreoidaler Therapie und der Charakterisierung des naturlichen Verlaufs der Immunhyperthyreose. Eine neue Multicenterstudie zur Rezidivprophylaxe mit Levothyroxin kommt zu folgenden Ergebnissen: Levothyroxin ist zur Rezidivprophylaxe nach erfolgreicher medikamentoser Therapie der Immunhyperthyreose nicht geeignet. Der TSH-Spiegel 4 Wochen nach medikamentosem Auslassversuch ist der starkste prognostische Marker. Rauchen und positive TSH-Rezeptorantikorper am Ende der antithyreoidalen Therapie sind als weitere Risikofaktoren einzustufen.

Published
2003
Full Text
View/download PDF

11. Frühoperation als Behandlungsmaßnahme der thyreotoxischen Krise

Author

A. Frilling, R. Hörmann, I. Reichmann, C. E. Broelsch, and Krause U

Subjects
Gynecology, medicine.medical_specialty, Transplant surgery, business.industry, Medicine, Surgery, business
Abstract

Einleitung: Die thyreotoxische Krise ist mit unter 1 % der Hyperthyreosen selten. Sie kann jedoch ein gravierendes diagnostisches und therapeutisches Problem darstellen. Methodik: Die Daten von 14 Patienten, die wegen einer thyreotoxischen Krise zwischen 1992–1999 operiert wurden, werden retrospektiv analysiert. Ergebnisse: Bei allen 10 Frauen und 4 Mannern zwischen 27 und 77 Jahren lag eine Schilddrusenerkrankung zu Grunde. Siebenmal wurde eine Autonomie, 4mal ein Morbus Basedow und 3mal eine Struma nodosa angegeben. Auslosende Ursache war 5mal die Einnahme von Amiodaron, 3mal die Gabe iodhaltiger Kontrastmittel, 2mal das Absetzen einer thyreostatischen Medikation und einmal eine hyperglykamische Entgleisung. In 3 Fallen wurde kein akutes Ereignis gefunden. Alle Patienten erhielten nach Auftreten der Symptome eine hochdosierte thyreostatische Therapie. Bei Aufnahme in unsere Klinik wurde ein Stadium I nach Herrmann bei 4 Patienten, Stadium II bei 3 Patienten und Stadium III bei 7 Patienten diagnostiziert. Die Operation erfolgte 2–18 Std nach Aufnahme bei uns. Als Operationsverfahren wurde 7mal eine beidseitige subtotale Schilddrusenresektion, 4mal eine Thyreoidektomie und 3mal eine Operation nach Dunhill durchgefuhrt. Bei 12 Patienten trat postoperativ eine rasche Besserung der Hyperthyreosesymptomatik ein. Zwei 77 und 74 Jahre alte Patientinnen verstarben einen bzw. 2 Tage postoperativ an kardialen Komplikationen bzw. Multiorganversagen. Bei beiden hatte eine thyreotoxische Krise im Stadium 3 vorgelegen. Schlusfolgerungen: Die Fruhoperation mus in das Therapiekonzept konservativ therapierefraktarer thyreotoxischer Krisen aufgenommen werden. Die besten Resultate werden erzielt, wenn der Operationszeitpunkt in Stadium I–II der Erkrankung gewahlt werden kann.

Published
2001
Full Text
View/download PDF

17. Autorenverzeichnis

Author

W. Domschke, M. Berger, W. Hohenberger, T. Meinertz, C. Vogelmeier, T. Sauerbruch, H.J. Kramer, S.C. Müller, H. Serve, M.M. Weber, B. Göke, J.R. Kalden, B. Manger, W. Rascher, B. Appenrodt, J. Atta, C. Auernhammer, I.B. Autenrieth, W. Avenhaus, M. Backmund, C. Bausewein, J. Behr, A. Behrens, R. Berner, F. Berr, N. Blank, E. Blind, M. Bockhorn, D. Bokemeyer, M. Böhm, G. Bönner, G.D. Borasio, K. Bork, J. Braun, H.-P. Bruch, T.H. Brümmendorf, U. Brunnberg, M. Brüwer, M.W. Büchler, C. Detter, S. Diederich, C. Diehm, J. Distler, D. Domagk, T. Dörner, H.-G. Dörr, H. Dralle, M. Dreyling, I. Ehlebracht-König, C. Ell, W. Enzensberger, H.-J. Epple, M. Fassnacht, H. Feußner, P. Fiegel, C. Fisang, D. Filipas, W. Fischbach, C.H. Flamme, J. Floege, U.R. Fölsch, C. Fottner, W. Frank, N. Frey, K. Friese, A. Frilling, M. Fröhner, P. Frühmorgen, P.R. Galle, S. Geidel, E. Genth, A. Gingelmaier, F.-D. Goebel, N. Gökbuget, R. Göke, K. Grabitz, M. Grünke, S. Hahner, W. Handrick, C. Hasslacher, E. Heidbreder, W. Heindel, V. Heinemann, J. Heitmann, H.W. Heiß, H. Hof, L. Hering, E. Hiller, A. Hirner, W.-K. Hofmann, E. Holler, A.H. Hölscher, G. Holtmann, J. Hölzen, J. Honegger, S. Hörle, K. Hörmann, R. Hörmann, I. Hornke, R.M. Huber, J. Hübner, R. Hummel, S. Irmscher, T. Jelinek, S. Jonas, E. Jost, H.H. Jung, G.J. Kahaly, M. Karaus, S. Katsoulis, H. Katus, H.P. Kessler, K. Kiehne, W. Kiess, M. Kindermann, Y. von Kodolitsch, H. Köhler, L. Köhler, M. Köhler, E. Kohne, H.-J. Kolb, J. Köninger, K. Koop, R. Köster, I. Kötter, H.J.J. Kramer, B. Kremer, P. Kroll, J.G. Kuipers, F. Lammert, M. Langer, M. Laukötter, H. Lehnert, B. Lembcke, M.M. Lerch, S. Liebe, A. Lieber, R. Loddenkemper, M. Löhr, H.-M. Lorenz, J. Lorenz, T. Löscher, M. Luster, G. Lux, K. Mann, J. Mayerle, U. Merle, H.-J. Meyer, C. Möbius, M. Moehler, H. Mönnikes, J. Mössner, S.A. Müller, T.J. Musholt, J. Nattermann, M. Neubrand, P. Neuhaus, B. Neundörfer, T. Nicolai, J. Nolde, H. Olschewski, J. Ostermeyer, C. Ott, S. Pahernik, U. Pankratius, K.G. Parhofer, B. Passlick, O. Pech, B. Pfaffenbach, T. Pfeiffer, A. Pilatz, T. Pohle, A. Pohl-Koppe, Katharina A. Ponto, H. Prange, A. Pruß, J. Rädle, B. Rauch, F. Raue, C. Reichel, C. Reindl, C. Reißfelder, Dipl.-Phys. J. Rendl, E. Rietschel, E. Rijcken, R. Roos, G. Rudofsky†, W. Samtleben, W. Sandmann, G. Sauter, K.P. Schaal, J.R. Schaefer, U. Schäfer-Graf, W. Schepp, M. Schlemmer, S. Schliep, H. Schmidt, B. Schmied, W. Schmiegel, A. Schießl, A. Schmid, A. Schneider, T. Schneider, J. Schölmerich, H. Scholz, U. Schönermarck, J. Schopohl, H. Schrezenmeier, H. Schulze-Koops, D. Schuppan, V. Schuster, G. Schüßler, O. Schwandner, T.F. Schwarz, R. Secknus, N. Senninger, O. Sezer, B.R. Simmen, U. Spengler, U. Stabenow-Lohbauer, R. Stebler, D. Steven, M. Sticherling, U. Strauch, C. Stremmel, W. Stremmel, B.A. Stuck, H. Stürz, C. Taube, O. Thulesius, K. Thurau, J.W. Thüroff, C. Tomiak, W. Uhl, D. Vallböhmer, T. Vogel, P. von den Driesch, F.M.E. Wagenlehner, A. Wagner, U. Wagner, K. Weber, W. Weidner, T. Weinke, B.T. Weis-Müller, M. Weiß, S. Willems, U. Wintergerst, M. Wirth, G.W. Wolkersdörfer, and M. Zeitz

Published
2011
Full Text
View/download PDF

18. [Organ manifestations of hyperthyroidism]

Author

R, Hörmann and P M, Schumm-Draeger

Subjects
Cardiovascular Diseases, Multiple Organ Failure, Humans, Hyperthyroidism
Abstract

Patients with hyperthyroidism tend to feel well and procrastinate the visit to the doctor and hence diagnosis of the disease. Among a whole variety of more or less distinct symptoms affecting many organs, cardiovascular disease is most prevalent and serious, because it relates to an increase in mortality of patients with hyperthyroidism. Recent epidemiological studies have clearly demonstrated that the disease already begins with the subclinical states of hyperthyroidism and, as a consequence, treatment should also be commenced early on. Novel insights into the mechanisms and actions of thyroid hormones at the pathophysiological level offer a potential for the development and future therapeutic use of selective hormone analogues. Despite the high frequency and importance of thyroid disorders, awareness appears to be decreasing and over-dosage of thyroid hormones in benign thyroid conditions is frequent. This review should emphasize that the thyroid gland affects the structure and function of a multitude of organs and, on the other hand, many symptoms and complaints, related to various organ systems, should raise suspicion of thyroid disease.

Published
2010

19. Heterogeneity of Autoantibodies against Thyroid Peroxidase in Autoimmune Thyroid Disease: Evidence against Antibodies Directly Inhibiting Peroxidase Activity as Regulatory Factors in Thyroid Hormone Metabolism

Author

Klaus Mann, Bernhard Saller, and R. Hörmann

Subjects
Adult, Male, endocrine system, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Graves' disease, Immunoblotting, Clinical Biochemistry, Enzyme-Linked Immunosorbent Assay, Autoantigens, Iodide Peroxidase, Biochemistry, Autoimmune Diseases, Epitopes, fluids and secretions, Endocrinology, Antigen, Thyroid peroxidase, Iron-Binding Proteins, Internal medicine, medicine, Humans, Hashimoto Disease, Immunosorbent Techniques, Aged, Autoantibodies, Autoimmune disease, biology, Chemistry, Biochemistry (medical), Thyroid, Thyroiditis, Autoimmune, Autoantibody, food and beverages, hemic and immune systems, Middle Aged, medicine.disease, Graves Disease, medicine.anatomical_structure, embryonic structures, biology.protein, Female, Peroxidase
Abstract

The close relationship between thyroid microsomal antigen and thyroid peroxidase (TPO) is now well established. The present study evaluates the significance of autoantibodies against TPO (anti-TPO-Abs) in the various forms and stages of autoimmune thyroid disease with respect to a possible heterogeneous nature and particularly to their influence on TPO activity. When measured by a RIA using purified human TPO, anti-TPO-Abs were highly correlated with microsomal antibodies determined by enyzme-linked immunosorbant assay (r = 0.96; P less than 0.0001) and with the results of a TPO immunoprecipitation assay using crude microsomal preparations (r = 0.76; P less than 0.001). Relating the results of these assays to the reactivities of patients' sera with thyroid microsomes in immunoblot under nonreducing and reducing conditions, discordant results could be observed in a few cases. Further analysis of these data indicate a heterogeneous nature of anti-TPO-Abs, which react with at least two antigenic domains of the TPO molecule. The comparative analysis of patients with hyperthyroid Graves' disease, patients with Graves' disease in clinical remission, and patients with hypothyroid Hashimoto's thyroiditis revealed no significant differences in the antibody spectrum. When evaluating the direct influence of anti-TPO-Abs on the activity of TPO under a rigorous methodological approach, we found no significant inhibition of the enzymatic activity by any of the sera investigated from patients with autoimmune thyroid disease compared to that in sera from normal controls. In conclusion, the data indicate a heterogeneous nature of anti-TPO-Abs. The spectrum of antigenic epitopes recognized by anti-TPO-Abs seems not to be significantly different in the various forms and stages of autoimmune thyroid disease. The lack of an inhibitory effect of autoantibodies on TPO activity argues against direct binding of autoantibodies to the enzymatic sites of TPO and indicates that they are not important factors in producing thyroid dysfunction in autoimmune thyroid disease.

Published
1991
Full Text
View/download PDF

20. Rekombinantes TSH und TSH-Analoga

Author

R Hörmann

Subjects
medicine.medical_specialty, Recombinant TSH, Endocrinology, medicine.diagnostic_test, business.industry, Internal medicine, Internal Medicine, medicine, business, Thyroid function tests
Published
1998
Full Text
View/download PDF

21. Antithyreoidale und TSH-suppressive Behandlung bei Morbus Basedow?

Author

R. Hörmann and K. Mann

Subjects
Gynecology, medicine.medical_specialty, business.industry, Internal Medicine, Medicine, Tsh suppression, business
Abstract

Ein kausal orientierter Therapieansatz der den zugrundeliegenden Immundefekt zu beseitigen oder wesentlich zu verbessern vermag, steht derzeit fur den Morbus Basedow nicht zur Verfugung. Die Behandlung ist daher im wesentlichen auf eine Wiederherstellung der euthyreoten Stoffwechsellage ausgerichtet. Grundsatzlich bieten sich gegenwartig 3 Therapieoptionen an: die medikamentose Behandlung mit Thyreostatika, die Radiojod-Therapie und die subtotale Thyreoidektomie. Traditionell sowie aus Kapazitatsgrunden der Durchfuhrbarkeit einer Radiojod-Therapie nimmt die thyreostatische Therapie in Deutschland einen hoheren Stellenwert ein als in anderen Landern, insbesondere den USA. In Umfragen unter Schilddrusenexperten wurden die unterschiedlichen Behandlungsgepflogenheiten dokumentiert [17]. Im Zusammenhang mit Bestrebungen die Bedingungen der Radiojod-Therapie im europaischen Verbund zu vereinheitlichen und die sehr strengen deutschen Strahlenschutzbestimmungen zu lockern, um damit erweiterte Kapazitaten fur die Durchfuhrung einer Radiojod-Therapie zu schaffen, steht eine Neubewertung der Indikation und kritische Bestandsaufnahme der Wirksamkeit der thyreostatischen Therapie an.

Published
1998
Full Text
View/download PDF

22. [Drug treatment of immune hyperthyroidism (Basedow disease). Patient selection, long-term follow-up and prevention of recurrence]

Author

B, Quadbeck, R, Hörmann, O E, Janssen, and K, Mann

Subjects
Thyroxine, Antithyroid Agents, Risk Factors, Secondary Prevention, Humans, Drug Therapy, Combination, Thyroid Function Tests, Long-Term Care, Graves Disease, Randomized Controlled Trials as Topic
Abstract

Since theraphy of Graves' disease is not directed towards the cause of the disease, medical theraphy is still the first choice and symptomatically effective in treating hyperthyroidism. Antithyroid drugs are effective in restoring euthyroidism in90% of the patients durning 4-6 weeks, but 30-50% of the patients experience relapse after withdrawal. Previous prospective randomized studies evaluated prognostic parameters and the use of levothyroxine for prevention of relapse of hyperthyroidism. Recent studies have addressed the period after withdrawal amd focused on the natural course of disease. The results of a recent prospective randomized and controlled multicenter study were as follows: supplementation of levothroxine does not prevent relapse of hyperthyroidism. Basal TSH (4 weeks after withdrawal of antithyroid drugs) is the best prognostic marker. Smoking and positive TSH-receptor-antibodies at the end of antithyroid theraphy are other risk factors.

Published
2003

24. [Early operation as a treatment measure in thyrotoxic crisis]

Author

I, Reichmann, A, Frilling, R, Hörmann, U, Krause, and C E, Broelsch

Subjects
Adult, Male, Survival Rate, Postoperative Complications, Cause of Death, Thyroidectomy, Humans, Female, Middle Aged, Thyroid Crisis, Aged, Retrospective Studies
Abstract

Thyroid storm is a rare disease, occurring in less than 1% of all thyrotoxicoses. Diagnosis and therapy still have serious problems.We review 14 patients who were operated on between 1992 and 1999 because of thyroid storm.All of the ten women and four men, aged 27 to 77 years, had an underlying thyroid disease. Autonomies were found in seven, Grave's disease in four, and a nodular goiter in three patients. The precipitating events were in five patients an antiarrhythmic therapy with amiodarone, on three occasions application of contrast medium, two times omission of antithyroid drugs and in one patient severe hyperglycemia with acidosis. In three patients no triggering factor was discovered. All patients were treated with high-dose antithyroid therapy. On admission, four patients were graded as stage-one thyroid crisis, three patients had stage-two and seven patients stage-three disease. All patients were operated on within 18 h of admission. Surgical procedure was in seven cases a bilateral subtotal resection, four times thyroidectomy, and in three patients a Dunhill procedure. After the operation, 12 patients improved rapidly. Two 77 and 74-year-old women died 1 or 2 days after the operation, respectively, one from heart failure and the other from multiple organ failure. Both had been diagnosed as thyrotoxic crisis stage three.Early operation should be adopted as a standard option in thyroid storm that cannot be controlled medically. Best results are achieved if the operation is done at stage one or two of the disease.

Published
2001

26. Evaluation of the LIAISON thyroid chemiluminescence immunoassays

Author

W, Hubl, D, Meissner, T, Demant, W, Becker, R, Hörmann, M, Bach, and M, Mack

Subjects
Immunoassay, Thyroid Hormones, Reference Values, Luminescent Measurements, Humans, Sensitivity and Specificity
Abstract

The LIAISON thyroid hormone assays TSH, FT4, FT3, T4 and T3 were evaluated by determining the imprecision, the reference ranges, the functional sensitivity (TSH), the dilution characteristics (accuracy) (FT4, FT3), and the recovery after spiking (TSH, T4, T3). Furthermore, inter-method comparisons were performed with following methods: Elecsys (Roche Diagnostics; TSH), AxSYM (Abbott Diagnostics; TSH, FT4, FT3, T4), ACS:180 (Bayer Diagnostics; all analytes), Amerlex-M (JohnsonJohnson; T4) and LISO-Phase (Techno Genetics; FT4). The fully automated LIAISON random access analyser is based on microparticle immunoassays and chemiluminescence. The coefficients of variation (CV) of intra-assay imprecision were between 0.2-6.0%, except for the control sample with extremely low TSH concentrations and low T3 concentrations. Inter-assay imprecision was performed by measuring controls covering the measuring range over a period of 9 to 20 days, with CVs ranging from 2.3-16.0%. The suitability of the sample material was determined by analysing serum and samples treated with EDTA, citrate or heparin in parallel. The results showed good correlations of the thyroid hormone concentrations between serum and plasma samples except for LIAISON FT3, for which lower results were observed with EDTA-plasma. The regression analysis of correlation studies gave slopes from 0.849 to 0.957 for TSH, from 1.023 to 1.375 for FT4, from 0.670 to 0.911 for FT3, from 0.917 to 1.166 for T4 and 1.00 for T3 depending on the concentration range and the method of comparison. The LIAISON FT4 assay showed a trend towards higher values in the high concentration range when compared with the ACS:180. The ranges of thyroid hormone concentrations determined in serum taken from apparently healthy subjects were found to be in accordance with published data. The clinical sample study confirmed that the LIAISON thyroid hormone assays are sensitive methods for the differentiation of euthyroid subjects and patients with hyper- and hypothyroidism. In conclusion, the automated thyroid hormone immunoassays on the random-access LIAISON immunoassay analyser proved to be very satisfactory, both from the analytical and the clinical point of view.

Published
2000

27. Frühoperation als Therapiekonzept der thyreotoxischen Krise

Author

A. Frilling, C. E. Broelsch, R. Hörmann, Krause U, and I. Reichmann

Abstract

Die thyreotoxische Krise entsteht in weniger als 1% der Hyperthyreosen. Operiert wurden 14 Patienten in 7 J., 10 Frauen und 4 Manner,Alter 27–77 J. Haufigste Grunderkrankung war die Autonomie, gefolgt vom M. Basedow. Auslosende Ursachen waren Aminodaron, iodhaltige Kontrastmittel, Absetzen von Thyreostatika und Ketoazidose. Bei 7 Patienten bestand ein Stadium III (Koma). Operiert wurde spatestens nach 18 Stunden. 12 Patienten besserten sich rasch. Zwei 77 und 74 Jahre alte Patientinnen im Stadium III verstarben nach 24–48 Stunden an kardialen Komplikationen. Die Fruhoperation ist Bestandteil des Therapiekonzeptes konservativ therapierefraktarer thyreotoxischer Krisen. Die besten Resultate werden erzielt, wenn der Operationszeitpunkt in Stadium I-II der Erkrankung gewahlt werden kann.

Published
2000
Full Text
View/download PDF

28. [Administration of levothyroxine in the treatment of Basedow disease]

Author

R, Hörmann

Subjects
Clinical Trials as Topic, Thyroxine, Animals, Humans, Multicenter Studies as Topic, Prospective Studies, Graves Disease, Randomized Controlled Trials as Topic
Abstract

Current therapy of Graves' disease is symptomatically effective in eliminating hyperthyroidism but is not directed towards the immunological cause of the disease. As a result, the majority of patients experience relapse of hyperthyroidism after antithyroid drugs have been discontinued and need to undergo radioiodine treatment or surgery. Improvement of efficacy of antithyroid drug therapy in inducing longlasting remission of Graves' disease has therefore been an elusive goal. A number of recent experimental and clinical trials have addressed the issue of improving and optimizing modalities of antithyroid therapy. In-vitro studies demonstrating direct immunosuppressive effects of thionamide drugs and encouraging results from a Japanese clinical trial suggested that maximum thyroid blockade and supplementation with levothyroxine might be effective in preventing relapse of disease. The superior efficacy of this approach could not be confirmed by others studies. On the other hand, these studies so far lack statistical power to prove a lack of effect of this approach. The issue of levothyroxine supplementation during antithyroid drug treatment should be separated from another issue of levothyroxine prophylaxis following successful treatment outcome. The latter question is currently addressed by a prospective randomized multicenter study.

Published
1999

40. [Results of selective goiter resection in functional autonomy]

Author

I, Reichmann, R, Hörmann, C, Zander, J, Friedrich, and U, Krause

Subjects
Male, Thyroxine, Postoperative Complications, Recurrence, Thyroidectomy, Humans, Female, Middle Aged, Thyroid Function Tests, Hyperthyroidism, Follow-Up Studies, Goiter, Nodular, Iodine
Abstract

In the period from 1989 to 1994 a surgical treatment of toxic nodular goiter was performed in 145 patients. An unifocal autonomous adenoma occurred in 69 cases, a multifocal disease 76 times. The operative strategy consisted in a bilateral resection 105 times, and unilateral resection 29 times. An excision of a single node was carried out in ten cases. In one operation a hemithyroidectomy on one side and a subtotal resection of the other lobe was done. In May 1996 an interrogation about the current thyroid function was performed. In 105 (72.4%) patients a re-evaluation was possible. Concerning the postoperative therapy for prevention of recurrent hyperthyroidism or goiter growth, 84 patients (80%) had been treated with thyroxin and/or iodine. Under this therapy, after a mean period of 36 months 94 patients (89.5%) were clinically euthyroid. Nine patients (8.6%) were hypothyroid. Two patients developed a recurrent hyperthyroidism. Both of them belonged to the group of patients with multifocal autonomies, and both had been treated with thyroxin postoperatively. In one case, recurrent goiter growth occurred that did not need a therapeutic intervention. This patient as well had been treated for a multinodular goiter originally. She had not been taking a specific medication postoperatively. We conclude that a functional resection of autonomic tissue in nodular goiters is efficient in controlling the thyroid metabolism. A medical prophylaxis was not able to prevent recurrent hyperthyroidism in two cases.

Published
1998

43. Ist die Hemithyreoidektomie als Standardeingriff bei suspekter Punktionszytologie gerechtfertigt?

Author

U. Krause, R. Hörmann, U. Schmidt, F. W. Eigler, and J. Friedrich

Abstract

Seit 1989 wurden bei 65 Patienten mit verdachtiger Feinnadelaspi-rationszytologie kalter Schilddrusensolitarknoten individuelle klinische Kriterien wie Anamnesedauer und Befund der ubrigen Schilddruse zur operativen Verfahrenswahl herangezogen. Schlieslich wurden in 37 Hemithyreoidektomiepraparaten 9 Karzinome nachgewiesen, nach 28 Resektionen fanden sich neben 2 papillaren Mikrokarzinomen bis jetzt ausschlieslich benigne Befunde. Trotz vergleichbar geringer perioperativer Morbiditat der Hemithyreoidektomie halten wir auch bei suspektem Zytologiebefund lediglich eine Resektion fur gerechtfertigt.

Published
1996
Full Text
View/download PDF

44. [Is hemithyroidectomy as standard intervention of suspicious puncture cytology justified?]

Author

J, Friedrich, U, Krause, U, Schmidt, R, Hörmann, and F W, Eigler

Subjects
Adult, Male, Adolescent, Biopsy, Needle, Carcinoma, Thyroid Gland, Middle Aged, Diagnosis, Differential, Adenocarcinoma, Papillary, Predictive Value of Tests, Adenocarcinoma, Follicular, Thyroidectomy, Humans, Female, Thyroid Neoplasms, Thyroid Nodule, Aged, Neoplasm Staging
Abstract

Since 1989, the operative treatment of 65 patients with suspicious fine-needle aspiration cytology of solitary thyroid nodules has been decided on individual clinical criteria such as the patient's history and morphology of the remaining thyroid tissue. Finally, 9 carcinomas were seen amongst 37 hemithyroidectomy specimens, out of 28 resected thyroid glands 2 were papillary microcarcinomas, whereas the others were benign specimens up until now. Despite a comparatively low perioperative morbidity of the hemithyroidectomy, we see thyroid resections justified in cases of suspicious cytology.

Published
1996

45. Clinical relevance of immunological markers in Graves' disease

Author

R. Hörmann, Klaus Mann, and Bernhard Saller

Subjects
business.industry, Endocrinology, Diabetes and Metabolism, Graves' disease, MEDLINE, Thyroid Gland, Receptors, Thyrotropin, General Medicine, medicine.disease, Graves Disease, Endocrinology, Immunology, Internal Medicine, medicine, Humans, Clinical significance, business, Biomarkers, Autoantibodies, Immunoglobulins, Thyroid-Stimulating
Published
1991

46. Biochemical Dissection of the Reactivity of TPO Antibodies

Author

B. Saller, K. Mann, and R. Hörmann

Subjects
chemistry.chemical_classification, endocrine system, biology, Chemistry, medicine.medical_treatment, Autoantibody, food and beverages, hemic and immune systems, Molecular biology, Epitope, fluids and secretions, Antigen, Thyroid peroxidase, embryonic structures, biology.protein, medicine, Thyroglobulin, Antibody, Receptor, Glycoprotein
Abstract

In patients with autoimmune thyroid disease the presence of autoantibodies against several distinct antigens including the TSH receptor, thyroglobulin, and the microsomal antigens (MAg) is well established. The MAg is a glycoprotein of an apparent molecular weight of about 100kDa [1–3], and its major antigenic component is thyroid peroxidase (TPO) [4–7]. Recently published studies have suggested a heterogeneous nature of autoantibodies directed against TPO (anti-TPO-Abs) [8] and reported that anti-TPO-Abs not only bound to TPO but also inhibited its enzymatic activity [9–12]. However, the important question of whether the antigenic determinants of TPO include its catalytic sites is presently controversial, since another study failed to find any inhibition of TPO activity by anti-TPO-Abs [4].

Published
1991
Full Text
View/download PDF

47. Medikamentöse Behandlung der Immunhyperthyreose (Typ Morbus Basedow).

Author

Dr. B. Quadbeck, R. Hörmann, O. E. Janssen, and K. Mann

Subjects
HYPERTHYROIDISM, THYROID antagonists, THYROXINE
Abstract

Copyright of Der Internist is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2003
Full Text
View/download PDF

49. Highly Sensitive Determination of TSH in the Follow-Up of TSH-Suppressive Therapy of Patients with Differentiated Thyroid Cancer

Author

B. Saller, Klaus Mann, R. Hörmann, U. Mehl, and E. Moser

Subjects
endocrine system, medicine.medical_specialty, Immunoradiometric assay, Triiodothyronine, endocrine system diseases, business.industry, Microgram, Levothyroxine, General Medicine, medicine.disease, Thyroid carcinoma, TRH stimulation test, Endocrinology, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, Thyroid cancer, hormones, hormone substitutes, and hormone antagonists, medicine.drug, Hormone
Abstract

Basal and TRH-stimulated TSH levels were determined in 72 patients with differentiated thyroid cancer on hormonal treatment, using a highly sensitive immunoradiometric assay (IRMAclon, Henning). 43 patients were under treatment with levothyroxine (T4), 29 patients with triiodothyronine (T3). In 33/43 patients (77%) under T4- and in 18/29 patients (62%) under T3-treatment basal TSH levels were below 0.1 mU/l and levels stimulated with 200 µg TRH i.v. were below 0.5 mU/l. 3 patients showed a significant response (to above 0.5 mU/l) in the TRH test despite basal values of less than 0.1 mU/l. In 2 patients with elevated basal TSH levels (0.23 and 0.60 mU/l, resp.) in the IRMAclon, total suppression of TSH secretion was suggested by a failure of TSH to rise after TRH. By retesting these samples in an own TSH IRMA, basal and stimulated TSH values were below 0.1 mU/l. In conclusion, basal and TRH-stimulated TSH levels are well correlated in most patients with thyroid cancer under hormonal treatment. However, in some cases (5/72) determination of basal TSH could not clearly define the degree of thyrotropic suppression. Thus, TRH testing is still necessary to establish definitely complete TSH suppression in patients with thyroid carcinoma under suppressive treatment.

Published
1988
Full Text
View/download PDF

50. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease

Author

Klaus Mann, Bernhard Saller, R. Hörmann, and R. Müller

Subjects
Adult, Male, endocrine system, medicine.medical_specialty, endocrine system diseases, Graves' disease, Group ii, Thyroid Gland, Disease, Gastroenterology, Radioligand Assay, Pharmacotherapy, Internal medicine, Drug Discovery, medicine, Humans, Genetics (clinical), Aged, Methimazole, Dose-Response Relationship, Drug, biology, business.industry, Thyroid, Autoantibody, General Medicine, Middle Aged, medicine.disease, Molecular medicine, Graves Disease, eye diseases, Thyroxine, medicine.anatomical_structure, Immunoglobulin G, Immunology, biology.protein, Triiodothyronine, Molecular Medicine, Female, Antibody, business, Follow-Up Studies, Immunoglobulins, Thyroid-Stimulating
Abstract

The prognostic value of the determinations of autoantibodies in Graves' disease is still questionable. So far, the role of different assay procedures used has not been intensively investigated. We simultaneously applied two different techniques, a radioreceptor assay and a T3 releasing in vitro assay, in the follow-up of patients with Graves' disease to directly compare the course of the antibody activities determined by these assays and to find out a prognostic significance of the composition of the antibody spectrum present. The initial activities of thyroid stimulating antibodies (TSAb) and TSH-binding inhibiting immunoglobulins (TBII) were not significantly correlated in patients before treatment. During a 12-month antithyroid medication antibody titres showed a concordant course in the majority of patients. In 6 of 25 patients, however, a discordant behaviour was clearly documented including dose-response curves. At the end of treatment, the patients could be divided into three groups: group I included 5 patients positive for both TSAb and TBII, group II 6 patients positive for TBII and negative for TSAb and group III 14 patients negative for both of them. During the following survey of 18 months all patients of group I, 2 patients of group II and 6 patients of group III experienced a relapse of hyperthyroidism. In conclusion, TSAb and TBII activities dissociate in some patients during antithyroid drug therapy. For the individual patient, the disappearance of both TSAb and TBII was no certain indicator for a longstanding remission of Graves' hyperthyroidism. The persistence of TSAb seems to be more reliably associated with persisting or rapidly relapsing disease than the persistence of TBII.

Published
1985
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results